Wouter B L van den Bossche1,2, Anne Kleijn1, Charlotte E Teunissen2,3, Jane S A Voerman2, Cristina Teodosio4, David P Noske5, Jacques J M van Dongen2,4, Clemens M F Dirven1, Martine L M Lamfers1. 1. Department of Neurosurgery, Brain Tumor Center, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 2. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 3. Department of Clinical Chemistry, Neuroscience Campus Amsterdam, Amsterdam, Netherlands. 4. Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands. 5. Department of Neurosurgery, VU University Medical Center, Amsterdam, Netherlands.
Abstract
Background: Immunosuppressive protumoral M2 macrophages are important in pathogenesis, progression, and therapy resistance in glioblastoma (GBM) and provide a target for therapy. Recently oncolytic virotherapy in murine models was shown to change these M2 macrophages toward the pro-inflammatory and antitumoral M1 phenotype. Here we study the effects of the oncolytic virotherapy Delta24-RGD in humans, using both in vitro models and patient material. Methods: Human monocyte-derived macrophages were co-cultured with Delta24-RGD-infected primary glioma stem-like cells (GSCs) and were analyzed for their immunophenotype, cytokine expression, and secretion profiles. Cerebrospinal fluid (CSF) from 18 Delta24-RGD-treated patients was analyzed for inflammatory cytokine levels, and the effects of these CSF samples on macrophage phenotype in vitro were determined. In addition, tumor macrophages in resected material from a Delta24-RGD-treated GBM patient were compared with 5 control GBM patient samples by flow cytometry. Results: Human monocyte-derived M2 macrophages co-cultured with Delta24-RGD-infected GSCs shifted toward an M1-immunophenotype, coinciding with pro-inflammatory gene expression and cytokine production. This phenotypic switch was induced by the concerted effects of a change in tumor-produced soluble factors and the presence of viral particles. CSF samples from Delta24-RGD-treated GBM patients revealed cytokine levels indicative of a pro-inflammatory microenvironment. Furthermore, tumoral macrophages in a Delta24-RGD-treated patient showed significantly greater M1 characteristics than in control GBM tissue. Conclusion: Together these in vitro and patient studies demonstrate that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.
Background: Immunosuppressive protumoral M2 macrophages are important in pathogenesis, progression, and therapy resistance in glioblastoma (GBM) and provide a target for therapy. Recently oncolytic virotherapy in murine models was shown to change these M2 macrophages toward the pro-inflammatory and antitumoral M1 phenotype. Here we study the effects of the oncolytic virotherapy Delta24-RGD in humans, using both in vitro models and patient material. Methods:Human monocyte-derived macrophages were co-cultured with Delta24-RGD-infected primary glioma stem-like cells (GSCs) and were analyzed for their immunophenotype, cytokine expression, and secretion profiles. Cerebrospinal fluid (CSF) from 18 Delta24-RGD-treated patients was analyzed for inflammatory cytokine levels, and the effects of these CSF samples on macrophage phenotype in vitro were determined. In addition, tumor macrophages in resected material from a Delta24-RGD-treated GBM patient were compared with 5 control GBM patient samples by flow cytometry. Results:Human monocyte-derived M2 macrophages co-cultured with Delta24-RGD-infected GSCs shifted toward an M1-immunophenotype, coinciding with pro-inflammatory gene expression and cytokine production. This phenotypic switch was induced by the concerted effects of a change in tumor-produced soluble factors and the presence of viral particles. CSF samples from Delta24-RGD-treated GBM patients revealed cytokine levels indicative of a pro-inflammatory microenvironment. Furthermore, tumoral macrophages in a Delta24-RGD-treated patient showed significantly greater M1 characteristics than in control GBM tissue. Conclusion: Together these in vitro and patient studies demonstrate that local Delta24-RGD therapy may provide a therapeutic tool to promote a prolonged shift in the protumoral M2 macrophages toward M1 in human GBM, inducing a pro-inflammatory and potentially tumor-detrimental microenvironment.
Authors: Jeroen de Vrij; S L Niek Maas; Kitty M C Kwappenberg; Rosalie Schnoor; Anne Kleijn; Lennard Dekker; Theo M Luider; Lot D de Witte; Manja Litjens; Miriam E van Strien; Elly M Hol; Jerome Kroonen; Pierre A Robe; Martine L Lamfers; Marco W Schilham; Marike L D Broekman Journal: Int J Cancer Date: 2015-04-07 Impact factor: 7.396
Authors: Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li Journal: Science Date: 2014-05-08 Impact factor: 47.728
Authors: Nelson C Di Paolo; Edward A Miao; Yoichiro Iwakura; Kaja Murali-Krishna; Alan Aderem; Richard A Flavell; Thalia Papayannopoulou; Dmitry M Shayakhmetov Journal: Immunity Date: 2009-07-02 Impact factor: 31.745
Authors: Konrad Gabrusiewicz; Aleksandra Ellert-Miklaszewska; Maciej Lipko; Malgorzata Sielska; Marta Frankowska; Bozena Kaminska Journal: PLoS One Date: 2011-08-25 Impact factor: 3.240
Authors: Rutger K Balvers; Zineb Belcaid; Sanne K van den Hengel; Jenneke Kloezeman; Jeroen de Vrij; Hiroaki Wakimoto; Rob C Hoeben; Reno Debets; Sieger Leenstra; Clemens Dirven; Martine L M Lamfers Journal: Viruses Date: 2014-08-12 Impact factor: 5.048
Authors: Zineb Belcaid; Cor Berrevoets; John Choi; Edward van Beelen; Eftychia Stavrakaki; Tessa Pierson; Jenneke Kloezeman; Denis Routkevitch; Mariëlle van der Kaaij; Alicia van der Ploeg; Dimitrios Mathios; Stefan Sleijfer; Clemens Dirven; Michael Lim; Reno Debets; Martine L M Lamfers Journal: Neurooncol Adv Date: 2020-02-03
Authors: R van de Ven; H de Haan; M López González; J van Eck van der Sluijs; W Dong; V W van Beusechem; T D de Gruijl Journal: Clin Exp Immunol Date: 2020-05-06 Impact factor: 4.330
Authors: Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro Journal: Front Oncol Date: 2021-06-08 Impact factor: 5.738